ELAN

TentativeAI Memo

Elanco Animal Health

As of 2026-08-25/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 beat and raised FY2026 outlook • 2026-08-05

Base target: $26 / p=55% prob

Biggest risk

The thesis depends on sustained innovation-product adoption, competitive pricing, and successful Befrena capacity expansion. Higher guidance also raises the execution bar, while leverage remains material and analyst revision evidence is unavailable.

Invalidation

Break below $21 or thesis failure.

What would change my mind?

The Q2 print showed broad operating momentum: revenue rose 10% year over year, organic constant-currency growth was 8%, and management cited Zenrelia and Credelio Quattro as major growth drivers. Raised full-year guidance and improving leverage support a constructive operating thesis. [#SEC-8K-2026-08-05]

Research note

Recommendation

—

Confidence

high

As of

2026-08-25

Base target

$26

p=55%

Bull target

$31

p=25%

Bear target

$21

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Innovation portfolio commercialization
Margin expansion and deleveraging
The Q2 print showed broad operating momentum: revenue rose 10% year over year, organic constant-currency growth was 8%, and management cited Zenrelia and Credelio Quattro as major growth drivers.

BearKey bullets

Analyst target counts, estimate revisions, options data, short interest, and social coverage are unavailable; direct animal-health peers improve context but differ in scale, product mix, and geographic exposure.
Befrena supply constraints and capacity expansion could limit commercial uptake.
Margin expansion and deleveraging may fall short of guidance, with net leverage still around 3.1x after Q2.

WatchKey bullets

Q2 beat and raised FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $26 (p=55%)

Target spread vs base: +21% / -19%

Scenario probabilities

Bull Target: $31 (p=25%)Base Target: $26 (p=55%)Bear Target: $21 (p=20%)

Commentary

News tone is positive following the Q2 beat and raised outlook. Stored earnings context described a positive market reception but reported ELAN at $22.75 versus $25.60 before earnings; the RankAlpha anchor later recovered to $24.42 on August 24. Analyst revisions and target changes are unavailable, so confidence remains constructive rather than aggressive. Direct animal-health references provide better context than broad biopharma peers, but they are not perfectly comparable.

As of 2026-08-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Innovation portfolio commercialization
Margin expansion and deleveraging

Scenarios

Bull Target (Scenario probability)

$31 / p=25% prob

Base Target (Scenario probability)

$26 / p=55% prob

Bear Target (Scenario probability)

$21 / p=20% prob

Analysis 2026-08-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.75

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Q2 beat and raised FY2026 outlook
Elanco reported Q2 revenue of $1.368 billion, 8% organic constant-currency growth, adjusted EBITDA of $288 million, and raised full-year revenue, EBITDA, EPS, innovation-revenue, and leverage targets. [#SEC-8K-2026-08-05]
Prob 95.00% • Move 7.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Innovation portfolio commercialization
2026-12-31
Zenrelia reached blockbuster status and approximately 18,000 U.S. clinics; Credelio Quattro exceeded 50% U.S. clinic penetration. H2 execution depends on continued share gains, clinic penetration, and Befrena capacity expansion. [#SEC-8K-2026-08-05]
Prob 75% • Move 18% • Priced-in 55%
Margin expansion and deleveraging
2026-12-31
Q2 adjusted EBITDA margin was 21.2%; full-year guidance implies approximately 13% midpoint EBITDA growth and a year-end net leverage target near 3.0x adjusted EBITDA. [#SEC-8K-2026-08-05]
Prob 70% • Move 9% • Priced-in 45%

Risks

Analyst target counts, estimate revisions, options data, short interest, and social coverage are unavailable; direct animal-health peers improve context but differ in scale, product mix, and geographic exposure.
Befrena supply constraints and capacity expansion could limit commercial uptake.
Margin expansion and deleveraging may fall short of guidance, with net leverage still around 3.1x after Q2.
Zenrelia and Credelio Quattro may face competitive pressure or slower clinic penetration.

Peers

Symbol	Summary
ZTS	Direct animal-health comparator spanning companion-animal and livestock medicines, vaccines, and diagnostics, but substantially larger and more diversified than Elanco. [Zoetis 2025 Annual Report](https://www.zoetis.com/_assets/pdf/corporate/zoetis-2025-annual-report.pdf)
IDXX	Direct animal-health operating reference focused primarily on veterinary diagnostics, practice-management software, and animal-health monitoring rather than therapeutics. [IDEXX 2025 Form 10-K](https://ir.idexx.com/sec-filings/all-sec-filings/content/0000874716-26-000038/idxx-20251231.htm)

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-25

Loading AI feed…

Symbol

Summary

ZTS

Direct animal-health comparator spanning companion-animal and livestock medicines, vaccines, and diagnostics, but substantially larger and more diversified than Elanco. [Zoetis 2025 Annual Report](https://www.zoetis.com/_assets/pdf/corporate/zoetis-2025-annual-report.pdf)

IDXX

Direct animal-health operating reference focused primarily on veterinary diagnostics, practice-management software, and animal-health monitoring rather than therapeutics. [IDEXX 2025 Form 10-K](https://ir.idexx.com/sec-filings/all-sec-filings/content/0000874716-26-000038/idxx-20251231.htm)